SG11202110085TA - Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof - Google Patents

Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Info

Publication number
SG11202110085TA
SG11202110085TA SG11202110085TA SG11202110085TA SG11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA
Authority
SG
Singapore
Prior art keywords
preparation
method therefor
btk inhibitor
ring derivative
pharmaceutical application
Prior art date
Application number
SG11202110085TA
Other languages
English (en)
Inventor
Chen Zhang
Yuting Liao
Jianmin Wang
Guozhi Zhu
Fei Ye
Pingming Tang
Xiaogang Chen
Zhenggang Huang
Shoutao Wu
Yao Li
Pangke Yan
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of SG11202110085TA publication Critical patent/SG11202110085TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202110085TA 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof SG11202110085TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910454977 2019-05-31
CN201910706239 2019-08-02
CN201910997078 2019-10-25
CN201911291561 2019-12-16
PCT/CN2020/093455 WO2020239103A1 (zh) 2019-05-31 2020-05-29 一种btk抑制剂环衍生物及其制备方法和药学上的应用

Publications (1)

Publication Number Publication Date
SG11202110085TA true SG11202110085TA (en) 2021-10-28

Family

ID=73553513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110085TA SG11202110085TA (en) 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Country Status (13)

Country Link
US (1) US11542266B1 (zh)
EP (1) EP3978496A4 (zh)
JP (1) JP2022534650A (zh)
KR (1) KR20220016049A (zh)
CN (2) CN113544130B (zh)
AU (1) AU2020281410A1 (zh)
BR (1) BR112021024131A2 (zh)
CA (1) CA3133004A1 (zh)
IL (1) IL287332A (zh)
MX (1) MX2021012756A (zh)
SG (1) SG11202110085TA (zh)
TW (1) TWI762939B (zh)
WO (1) WO2020239103A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220016049A (ko) * 2019-05-31 2022-02-08 스촨 하이스코 파마수티컬 씨오., 엘티디 Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
IL295101A (en) 2020-01-29 2022-09-01 Foghorn Therapeutics Inc materials and their use
WO2021184154A1 (en) 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
US20230248833A1 (en) 2020-07-07 2023-08-10 Sichuan Haisco Pharmaceutical Co., Ltd. Compound having btk kinase degrading activity, and preparation method and pharmaceutical use therefor
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
KR20230091088A (ko) * 2020-09-09 2023-06-22 하이스코 파마수티컬즈 피티이. 엘티디. Btk 분해용 화합물의 염, 이의 결정 형태, 및 이의 약제에서의 용도
WO2022111448A1 (zh) * 2020-11-25 2022-06-02 四川海思科制药有限公司 一种btk降解剂的制备方法
WO2022111449A1 (zh) * 2020-11-25 2022-06-02 四川海思科制药有限公司 一种btk降解剂的制备方法
CN116568679A (zh) * 2020-11-25 2023-08-08 四川海思科制药有限公司 一种btk降解剂的制备方法
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
CN115521313B (zh) * 2021-06-24 2023-11-03 山东大学 一种降解btk蛋白的化合物及其制备方法和应用
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
US20230137175A1 (en) * 2021-08-17 2023-05-04 Endotarget Inc. Compounds and methods for the targeted degradation of bruton's tyrosine kinase
WO2023072270A1 (zh) * 2021-10-29 2023-05-04 百极弘烨(南通)医药科技有限公司 Protac化合物、含其的药物组合物及其制备方法和应用
WO2023125907A1 (en) * 2021-12-30 2023-07-06 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
JP2010522170A (ja) * 2007-03-20 2010-07-01 セルジーン コーポレイション ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102869664A (zh) * 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并嘧啶类激酶抑制剂
DK2975042T3 (en) * 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
WO2012096928A2 (en) * 2011-01-10 2012-07-19 Glaxosmithkline Llc Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren
CA2910873A1 (en) * 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP6510510B2 (ja) * 2013-07-11 2019-05-08 ベータ ファーマシューティカルズ カンパニー リミテッド プロテインチロシンキナーゼモジュレーター及び使用方法
WO2016004305A2 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN104530046B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 二氮杂螺类化合物及其在药物中的应用
WO2017029601A1 (en) * 2015-08-17 2017-02-23 Lupin Limited Heteroaryl derivatives as parp inhibitors
WO2017054702A1 (zh) * 2015-09-28 2017-04-06 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
AU2016341520C1 (en) * 2015-10-21 2021-07-22 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN109563099B (zh) 2016-08-16 2023-02-03 百济神州有限公司 一种化合物的晶型、其制备和用途
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN106831787B (zh) 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
CA3054403A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
CN109422752B (zh) * 2017-09-03 2023-04-07 上海美志医药科技有限公司 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
CN109422696B (zh) * 2017-09-04 2020-10-30 北京睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
KR20220016049A (ko) * 2019-05-31 2022-02-08 스촨 하이스코 파마수티컬 씨오., 엘티디 Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용

Also Published As

Publication number Publication date
BR112021024131A2 (pt) 2022-01-11
AU2020281410A1 (en) 2021-10-07
CN118027041A (zh) 2024-05-14
KR20220016049A (ko) 2022-02-08
US11542266B1 (en) 2023-01-03
EP3978496A1 (en) 2022-04-06
TW202110825A (zh) 2021-03-16
IL287332A (en) 2021-12-01
TWI762939B (zh) 2022-05-01
WO2020239103A1 (zh) 2020-12-03
MX2021012756A (es) 2022-04-18
CA3133004A1 (en) 2020-12-03
EP3978496A4 (en) 2022-08-17
JP2022534650A (ja) 2022-08-03
CN113544130A (zh) 2021-10-22
CN113544130B (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
IL287332A (en) A ring derivative of btk inhibitor, its preparation method and pharmaceutical application
SG11202006409TA (en) Biaryl derivative, preparation method therefor and pharmaceutical use thereof
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3486242A4 (en) OXOPICOLINAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL USE THEREOF
EP3275867A4 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
EP3632907A4 (en) N- (AZAARYL) CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, MANUFACTURING METHOD FOR IT AND USE THEREOF
EP3805231A4 (en) INHIBITOR CONTAINING A TRICYCLIC DERIVATIVE, METHOD FOR PREPARING IT AND ITS APPLICATION
EP4056571A4 (en) TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL276244A (en) A pharmaceutical preparation for the eyes, a method for its preparation and its application
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
EP3653202A4 (en) PHARMACEUTICAL PREPARATION AND MANUFACTURING PROCESSES FOR IT
EP3858833A4 (en) AMINONORDECANE DERIVATIVE, METHOD FOR PREPARATION AND USE
EP4079734A4 (en) TRIAZOLOPYRIDAZINE DERIVATIVE, METHOD FOR PREPARING IT, PHARMACEUTICAL COMPOSITION THEREOF AND CORRESPONDING USE
EP3450450A4 (en) VANCOMYCINE DERIVATIVE PRODUCTION, PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3406606A4 (en) HETEROCYCLIC NITROGEN AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHRAMACEUTICAL APPLICATION
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
IL291557A (en) Antibody, pharmaceutical composition and method
EP3730484A4 (en) INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PROCESS FOR PREPARATION AND APPLICATION
IL282218A (en) New aminopyrimidonyl compounds, a process for their preparation and pharmaceutical preparations containing them
EP4053311A4 (en) DRUG AND HALF-LIFE EXTENSION LIBRARY THEREOF, CORRESPONDING PREPARATION METHOD AND USE THEREOF
EP3851438A4 (en) BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC AND APPLICATION OF THE SAME
EP3988547A4 (en) INDAZOLE DERIVATIVE, METHOD FOR PREPARATION AND PHARMACEUTICAL APPLICATION
EP3805212A4 (en) 3-OXAZOLINONE COMPOUND, METHOD FOR PREPARING THEREOF, AND PHARMACEUTICAL USE THEREOF
EP3858812A4 (en) MDM2 INHIBITOR, METHOD FOR PREPARING IT, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
EP4137124A4 (en) SOLID PHARMACEUTICAL PREPARATION, ITS PREPARATION METHOD AND ITS USE